Clinical Trials on Fallopian Tube Cancer in United States

Total 24127 results

National Cancer Institute (NCI)

Completed

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Sarcoma

United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content | Head and Neck...

United States, Belgium, United Kingdom
Toray Industries, Inc

Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Cholangiocarcinoma | Bladder Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer | Palpable Subcutaneous Malignant Lesions

United States, France
National Cancer Institute (NCI)

Completed

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Undifferentiated Adenocarcinoma

United States
OvaGene Oncology, Inc.

Unknown

DNA Single Nucleotide Polymorphisms as Predictors of Toxicity

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
University of Michigan

Completed

Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients

Urogenital Neoplasms | Uterine Cervical Neoplasms | Uterine Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms

United States
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
National Cancer Institute (NCI)

Terminated

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

United States, Australia, France, Poland
OncoC4, Inc.
Merck Sharp & Dohme LLC; GOG Foundation

Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Spain, Canada, Australia, United Kingdom, France
Bio-Path Holdings, Inc.

Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Solid Tumor | Endometrial Cancer | Peritoneal Cancer | Solid Tumor, Adult

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Primary Peritoneal Cancer | Fallopian Tube | High Grade Serous Ovarian

United States
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Poland, Korea, Republic of, United States, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Avenge Bio, Inc

Terminated

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Primary Peritoneal Carcinoma | Neoplasm, Ovarian | Adenocarcinoma Ovary | Serous Adenocarcinoma of Ovary | Serous Adenocarcinoma of Primary Peritoneum | High Grade Serous Adenocarcinoma

United States
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
Eli Lilly and Company

Completed

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Genital Neoplasms, Female | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Pelvic Neoplasms

United States
Kite, A Gilead Company

Terminated

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Multiple Myeloma | Ovarian Cancer | Fallopian Tube Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Estrogen Receptor Positive | Postmenopausal

United States
Novartis Pharmaceuticals

Completed

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

Netherlands, Canada, United States, Slovakia, United Kingdom
National Cancer Institute (NCI)

Completed

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Fallopian Tube Cancer | Uterine Carcinosarcoma | Stage IV Ovarian Epithelial Cancer | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Carcinosarcoma | Female Reproductive... and other conditions

United States, Canada
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
University of Colorado, Denver

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian... and other conditions

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer

Depression | Pain | Fatigue | Pseudomyxoma Peritonei | Peritoneal Carcinomatosis | Recurrent Endometrial Carcinoma | Anxiety Disorder | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Recurrent Breast Cancer | Leydig Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Ovarian... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Numab Therapeutics AG

Terminated

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Colorectal Cancer | Fallopian Tube Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Peritoneal Carcinoma | Head and Neck Squamous Cell Carcinoma | Ovarian Carcinoma | Squamous Cell Carcinoma

United States, Taiwan, Spain
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Jonsson Comprehensive Cancer Center
TetraLogic Pharmaceuticals; California Institute for Regenerative Medicine... and other collaborators

Withdrawn

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Ovarian Cancer | Peritoneal Cancer | Fallopian Tubes

United States
Pierian Biosciences

Completed

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

Adenocarcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Adult Solid Neoplasm

United States, Canada
National Cancer Institute (NCI)

Completed

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States

Clinical Trials on Fallopian Tube Cancer in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations